Product image of Imipenem/Cilastatina Kabi (Cilastatin Sodium, Imipenem Monohydrate) supplied by GNH India

Imipenem/Cilastatina Kabi

Active Ingredient:
Cilastatin Sodium, Imipenem Monohydrate
Origin:
EU

Imipenem/Cilastatina Kabi (Cilastatin Sodium, Imipenem Monohydrate)

Imipenem/Cilastatin, the active ingredient in Imipenem/Cilastatin Kabi, is a carbapenem antibiotic presented as a sterile powder for reconstitution for intravenous use. It treats severe bacterial infections, including intra‑abdominal, urinary, skin, and respiratory infections, in hospitalized adult patients.
GNH India supplies Imipenem/Cilastatin Kabi as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres, oncology centres, pharmacies and clinics worldwide.

Manufacturer / TM Owner

Fresenius Kabi Pharma Portugal, Lda.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Imipenem/Cilastatin is a broad‑spectrum carbapenem used for serious bacterial infections affecting various organ systems.

  • Complicated intra‑abdominal infections: provides rapid bacterial eradication in the peritoneal cavity.
  • Complicated urinary tract infections: eliminates resistant uropathogens causing pyelonephritis and cystitis.
  • Complicated skin and soft tissue infections: clears mixed Gram‑positive and Gram‑negative organisms.
  • Hospital‑acquired and ventilator‑associated pneumonia: penetrates lung tissue to treat resistant pneumonia pathogens.
  • Severe sepsis: offers bactericidal activity against a wide range of pathogens in systemic infection.

How It Works

  • Imipenem binds to penicillin‑binding proteins, inhibiting the final transpeptidation step of bacterial cell‑wall synthesis, which leads to cell lysis. Cilastatin is co‑administered to inhibit renal dehydropeptidase‑I, preventing rapid degradation of imipenem and thereby increasing its plasma concentration and antibacterial efficacy.

Side Effects

Adverse reactions may occur with any antimicrobial therapy.

Common Side Effects

  • Nausea: mild to moderate gastrointestinal upset.
  • Diarrhea: may be watery and self‑limiting.
  • Vomiting: occasional emesis after infusion.
  • Headache: transient cranial discomfort.
  • Rash: erythematous skin eruption.
  • Elevated liver enzymes: transient increase in ALT/AST.

Serious or Rare Side Effects

  • Seizures: especially in patients with renal impairment or CNS disorders.
  • Anaphylaxis: severe allergic reaction requiring immediate medical attention.
  • Clostridioides difficile‑associated diarrhea: colitis due to disruption of normal flora.
  • Neutropenia: marked reduction in neutrophil count.
  • Thrombocytopenia: decreased platelet levels.
  • Renal impairment: worsening kidney function in susceptible individuals.

Precautions & Warnings

Careful assessment and monitoring are required when using this intravenous carbapenem.

  • Assess renal function: dose adjustment may be needed in renal insufficiency.
  • Monitor for seizures: avoid in patients with a history of CNS disorders.
  • Evaluate hypersensitivity: discontinue if signs of an allergic reaction appear.
  • Use caution with concomitant nephrotoxic agents: increased risk of kidney injury.
  • Adjust dose in severe renal impairment: follow prescriber guidance.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze.

Avoid Interactions

Imipenem/Cilastatin can alter the pharmacokinetics of several co‑administered drugs.

Major Interactions (Avoid)

  • Valproic acid: carbapenems reduce serum valproate levels, risking seizure breakthrough.
  • Other carbapenems: concurrent use may increase toxicity without added benefit.
  • High‑dose aminoglycosides: combined nephrotoxic potential.

Moderate Interactions (Monitor Closely)

  • Diuretics: may enhance renal electrolyte loss; monitor electrolytes.
  • Warfarin: possible alteration of INR; check coagulation status regularly.
  • Oral contraceptives: reduced efficacy; advise alternative contraception.

Frequently Asked Questions

Imipenem/Cilastatin Kabi is indicated for severe bacterial infections such as complicated intra‑abdominal infections, complicated urinary tract infections, complicated skin and soft tissue infections, hospital‑acquired or ventilator‑associated pneumonia, and severe sepsis. It is reserved for patients who need broad‑spectrum coverage against resistant Gram‑negative and Gram‑positive organisms.

The drug combines imipenem, which binds to penicillin‑binding proteins and blocks the final step of bacterial cell‑wall synthesis, with cilastatin, an inhibitor of renal dehydropeptidase‑I. Cilastatin prevents rapid degradation of imipenem in the kidneys, maintaining therapeutic drug levels and ensuring potent bactericidal activity.

Dosing is individualized by the prescribing clinician based on the type and severity of infection, patient weight, and renal function. The prescriber determines the exact amount, infusion rate, and duration of therapy to achieve optimal efficacy while minimizing toxicity.

The pregnancy safety category for Imipenem/Cilastatin is not definitively established. It should be used only when the potential benefit justifies any potential risk to the fetus. Breastfeeding mothers should consult their healthcare provider, as the drug may be excreted in breast milk.

To place an order, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including any cold‑chain requirements), and necessary import documentation.

Both imipenem/cilastatin and meropenem belong to the carbapenem class and offer broad‑spectrum activity. Imipenem is often combined with cilastatin to protect it from renal degradation, whereas meropenem is administered without an inhibitor. Clinical choice depends on local resistance patterns, patient renal function, and specific infection site.

The product should be stored at 2‑8 °C, protected from light, and kept in its original packaging. Do not freeze or shake the reconstituted solution. Once prepared, the solution should be used within the time frame recommended by the manufacturer to maintain potency.

Imipenem/Cilastatin is supplied as a sterile powder for intravenous infusion. After reconstitution with the appropriate diluent, the solution is administered by slow IV infusion over 30‑60 minutes, following the dosing schedule prescribed by the treating physician.

The most critical adverse events include seizures, especially in patients with renal impairment or pre‑existing CNS disorders; severe allergic reactions such as anaphylaxis; and Clostridioides difficile‑associated colitis, which can lead to life‑threatening diarrhea. Prompt medical attention is required if any of these occur.

Patients with a known hypersensitivity to imipenem, cilastatin, or any other carbapenem should avoid this medication. Caution is also advised for individuals with severe renal impairment, as dose adjustments are necessary, and for those with a history of seizures or central nervous system disorders.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Cilastatin Sodium, Imipenem Monohydrate

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT